Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02476682
Registration number
NCT02476682
Ethics application status
Date submitted
10/06/2015
Date registered
19/06/2015
Date last updated
29/06/2023
Titles & IDs
Public title
Non-invasive Risk Stratification of CR AMN/SSP
Query!
Scientific title
Evaluation of Stool and Blood Based Tests for Colorectal Advanced Mucosal Neoplasia
Query!
Secondary ID [1]
0
0
HREC2014/9/4.4(4079)
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FIT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Adenomatous Polyps
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Other interventions - blood or stool samples will be collected
Normal subjects - blood or stool samples will be collected from people referred for screening colonoscopy
Colorectal cancer - blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
Polyps <10mm and no high risk features - blood or stool samples will be collected from people with no polyps or low risk polyps (\<10mm, no villous component or dysplasia) detected at colonoscopy
Advanced Mucosal Neoplasia - blood or stool samples will be collected from people with AMN detected at resection
Sessile Serrated Adenoma - blood or stool samples will be collected from people with SSP detected at resection
non-colorectal neoplastic disease - Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.
Other interventions: blood or stool samples will be collected
blood or stool samples will be collected
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Demographics
Query!
Assessment method [1]
0
0
Data to adequately describe demographic situations of each participant.
Query!
Timepoint [1]
0
0
1 day
Query!
Primary outcome [2]
0
0
Level of methylated DNA in circulation
Query!
Assessment method [2]
0
0
The process will use an automated extraction procedure incorporating state-of-the-art magnetic silica-coated beads on a QIASymphony (Qiagen). The extracted DNA is bisulphite-converted and further purified (automated on a QIACube HT liquid handler) prior to analyzing 12uL of bis-DNA in a multi-plexed (BCAT1, IKZF1, ACTB (control assay)) real-time PCR for measuring the methylation levels of target amplicons.
Query!
Timepoint [2]
0
0
5 years
Query!
Primary outcome [3]
0
0
Level of haemoglobin in stool
Query!
Assessment method [3]
0
0
Suspended stool collected in the HM-JACKarc sampling device will be processed for Hb measurements using commercially available reagents and the bench-top analyser instrument, HM-JACKarc, according to manufacturer recommendation (Kyowa Medex Co Ltd, Japan). Measured haemoglobin concentrations will be reported as ug Hb/g stool. A 20 ug Hb/g stool a cut-off concentration will be used for qualitative reporting.
Query!
Timepoint [3]
0
0
5 years
Query!
Primary outcome [4]
0
0
Demographics
Query!
Assessment method [4]
0
0
Data to adequately decribe the clinical situations of each participant.
Query!
Timepoint [4]
0
0
1 day
Query!
Eligibility
Key inclusion criteria
* Individuals capable and willing of proving satisfactory informed consent
* Individuals with colonic lesions larger than 20mm
* Individuals diagnosed with laterally spreading or sessile polyp morphology
* Individuals schedules for screening colonoscopy and with no prior history of CRC
* Ability and willingness to collect stool sample at home
* Ability and willingness to undergo venepuncture procedure
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Individuals not able or unwilling to provide informed consent
* Individuals less than 18 year of age
* Individuals who undergo an incomplete colonoscopy or resection, which raises doubt as to the status of the colon (post-hoc exclusion)
* Individuals with a prior history of CRC
* Individuals with a history of Irritable Bowel Disease (IBD), hereditary nonpolyposis colorectal cancer (HNPCC) or Familial adenomatous polyposis (FAP)
* Individuals with bleeding diathesis
* Pregnancy
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/01/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
205
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Westmead Endoscopy Unit - Westmead
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Professor Michael Bourke
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine the clinical utility of stool and blood methylation tests for detection of advanced mucosal neoplasia (AMN) and sessile serrated polyps (SSP).
Query!
Trial website
https://clinicaltrials.gov/study/NCT02476682
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Michael J Bourke, MBBS FRACP
Query!
Address
0
0
Westmead Hospita;
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02476682
Download to PDF